中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2009年
24期
33-35
,共3页
膀胱癌%CD24蛋白%预后指标
膀胱癌%CD24蛋白%預後指標
방광암%CD24단백%예후지표
Bladder carcinoma%CD24%Immunohistochemistry
目的 探讨CD24蛋白在膀胱癌中的表达及其与膀胱癌临床特征的关系.方法 采用免疫组化方法对43例膀胱肿瘤、10例正常膀胱组织中CD24的表达进行检测.结果 CD24蛋白主要表达于膀胱恶性肿瘤细胞的细胞膜和胞浆中,其阳性例数为27例,阳性率为62.8%,在正常膀胱组织中l例阳性表达,阳性率10%.在43例膀胱肿瘤石蜡标本中,CD24表达强度与肿瘤分级和分期有关,恶性程度高的肿瘤阳性表达高于恶性程度低的肿瘤,浸润性癌也高于非浸润性癌(P<0.05).结论 ①CD4在膀胱癌中的表达明显高于在正常膀胱组织中的表达.②CD24高表达与膀胱移行细胞癌的分化和浸润性进展密切相关.③CD24高表达可能成为判断膀胱移行细胞癌预后的一个重要指标.
目的 探討CD24蛋白在膀胱癌中的錶達及其與膀胱癌臨床特徵的關繫.方法 採用免疫組化方法對43例膀胱腫瘤、10例正常膀胱組織中CD24的錶達進行檢測.結果 CD24蛋白主要錶達于膀胱噁性腫瘤細胞的細胞膜和胞漿中,其暘性例數為27例,暘性率為62.8%,在正常膀胱組織中l例暘性錶達,暘性率10%.在43例膀胱腫瘤石蠟標本中,CD24錶達彊度與腫瘤分級和分期有關,噁性程度高的腫瘤暘性錶達高于噁性程度低的腫瘤,浸潤性癌也高于非浸潤性癌(P<0.05).結論 ①CD4在膀胱癌中的錶達明顯高于在正常膀胱組織中的錶達.②CD24高錶達與膀胱移行細胞癌的分化和浸潤性進展密切相關.③CD24高錶達可能成為判斷膀胱移行細胞癌預後的一箇重要指標.
목적 탐토CD24단백재방광암중적표체급기여방광암림상특정적관계.방법 채용면역조화방법대43례방광종류、10례정상방광조직중CD24적표체진행검측.결과 CD24단백주요표체우방광악성종류세포적세포막화포장중,기양성례수위27례,양성솔위62.8%,재정상방광조직중l례양성표체,양성솔10%.재43례방광종류석사표본중,CD24표체강도여종류분급화분기유관,악성정도고적종류양성표체고우악성정도저적종류,침윤성암야고우비침윤성암(P<0.05).결론 ①CD4재방광암중적표체명현고우재정상방광조직중적표체.②CD24고표체여방광이행세포암적분화화침윤성진전밀절상관.③CD24고표체가능성위판단방광이행세포암예후적일개중요지표.
Objective To investigate the clinical significance of CD24 protein expression in human bladder carcinoma.Methods Immunohistochemical method was usecl in detecting CD24 in 43 TCCB,10 normal bladder mucosa.Resuits CD24 protein was mainly localized at cellular membrane and cytoplasm of malignant cell (positive case was 27),but only one case expressed in normal bladder mucosa (n = 10).The intensity of CD24 expression was associated with tumor grade and stage in 43 paraffin embedded specimens of BTCC.The level of CW24 expression was higher in grade Ⅲ tumor than in grade Ⅰ,and it was higher in invasive tumor(T1-T4) than noinvasive tumor(Ta) (P <0.05).Conclusions The expression of CD24 is significantly higher in TCCB than in normal bladder tissue.The high expression of CD24 is extremely associated withtumor cells differentiation and invasion in bladder carcinoma.CD24 may be a reliable prognostic marker in bladder transitional cell carcinoma.